@article{9e137c56ee954a72ab025fed4552c9b1,
title = "Clinical Benefit of Hospitalization for Older Adults With Unexplained Syncope: A Propensity-Matched Analysis",
abstract = "Study objective: Many adults with syncope are hospitalized solely for observation and testing. We seek to determine whether hospitalization versus outpatient management for older adults with unexplained syncope is associated with a reduction in postdisposition serious adverse events at 30 days. Methods: We performed a propensity score analysis using data from a prospective, observational study of older adults with unexplained syncope or near syncope who presented to 11 emergency departments (EDs) in the United States. We enrolled adults (≥60 years) who presented with syncope or near syncope. We excluded patients with a serious diagnosis identified in the ED. Clinical and laboratory data were collected on all patients. The primary outcome was rate of post-ED serious adverse events at 30 days. Results: We enrolled 2,492 older adults with syncope and no serious ED diagnosis from April 2013 to September 2016. Mean age was 73 years (SD 8.9 years), and 51% were women. The incidence of serious adverse events within 30 days after the index visit was 7.4% for hospitalized patients and 3.19% for discharged patients, representing an unadjusted difference of 4.2% (95% confidence interval 2.38% to 6.02%). After propensity score matching on risk of hospitalization, there was no statistically significant difference in serious adverse events at 30 days between the hospitalized group (4.89%) and the discharged group (2.82%) (risk difference 2.07%; 95% confidence interval –0.24% to 4.38%). Conclusion: In our propensity-matched sample of older adults with unexplained syncope, for those with clinical characteristics similar to that of the discharged cohort, hospitalization was not associated with improvement in 30-day serious adverse event rates.",
author = "Probst, {Marc A.} and E. Su and Weiss, {Robert E.} and Yagapen, {Annick N.} and Malveau, {Susan E.} and Adler, {David H.} and Aveh Bastani and Baugh, {Christopher W.} and Caterino, {Jeffrey M.} and Clark, {Carol L.} and Diercks, {Deborah B.} and Hollander, {Judd E.} and Nicks, {Bret A.} and Nishijima, {Daniel K.} and Shah, {Manish N.} and Stiffler, {Kirk A.} and Storrow, {Alan B.} and Wilber, {Scott T.} and Sun, {Benjamin C.}",
note = "Funding Information: Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Research reported in this publication was supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under award R01HL111033. Dr. Probst is supported by a Career Development Award from the NHLBI (K23HL132052). Dr. Shah reports receiving research funding from Roche and Omron, Inc. Dr. Adler reports receiving research funding from Roche. Dr. Bastani reports receiving research funding from Radiometer and Portola and being a consultant for Portola. Dr. Baugh reports receiving advisory board and speaker's fees from Roche, research funding from Janssen and Boehringer Ingelheim, and consulting and advisory board fees from Janssen. Dr. Caterino reports receiving funding from AstraZeneca. Dr. Clark reports receiving research funding from Radiometer, Ortho Clinical Trials, Janssen, Pfizer, NIH, Portola, BioCryst, GlaxoSmithKlein, Hospital Quality Foundation, and Abbott, and is also a consultant for Portola, Janssen, and Hospital Quality Foundation. Dr. Diercks is a consultant for Janssen and Roche; has received institutional research support from Novartis, Ortho Scientific, and Roche; and is on the editorial board for Academic Emergency Medicine and Circulation. Dr. Hollander reports receiving research funding from Alere, Siemens, Roche, Portola, and Trinity. Dr. Nishijima reports receiving honorarium from Pfizer. Dr. Storrow is a consultant for Siemens and Quidel and is on the data and safety monitoring board for Trevena. Dr. Sun is a consultant for Medtronic. Author contributions: MAP and BCS designed the study and drafted the article. BCS obtained funding. ANY and SEM were responsible for data collection and management. ES and REW provided statistical advice on study design and analyzed the data. All authors contributed substantially to article revision and approved the final report for submission. ES, REW, ANY, SEM, and BCS had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. BCS takes responsibility for the paper as a whole. Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (seewww.icmje.org). Research reported in this publication was supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under award R01HL111033. Dr. Probst is supported by a Career Development Award from the NHLBI ( K23HL132052). Dr. Shah reports receiving research funding from Roche and Omron, Inc. Dr. Adler reports receiving research funding from Roche. Dr. Bastani reports receiving research funding from Radiometer and Portola and being a consultant for Portola. Dr. Baugh reports receiving advisory board and speaker's fees from Roche, research funding from Janssen and Boehringer Ingelheim, and consulting and advisory board fees from Janssen. Dr. Caterino reports receiving funding from AstraZeneca. Dr. Clark reports receiving research funding from Radiometer, Ortho Clinical Trials, Janssen, Pfizer, NIH, Portola, BioCryst, GlaxoSmithKlein, Hospital Quality Foundation, and Abbott, and is also a consultant for Portola, Janssen, and Hospital Quality Foundation. Dr. Diercks is a consultant for Janssen and Roche; has received institutional research support from Novartis, Ortho Scientific, and Roche; and is on the editorial board for Academic Emergency Medicine and Circulation. Dr. Hollander reports receiving research funding from Alere, Siemens, Roche, Portola, and Trinity. Dr. Nishijima reports receiving honorarium from Pfizer. Dr. Storrow is a consultant for Siemens and Quidel and is on the data and safety monitoring board for Trevena. Dr. Sun is a consultant for Medtronic. Publisher Copyright: {\textcopyright} 2019 American College of Emergency Physicians",
year = "2019",
month = aug,
doi = "10.1016/j.annemergmed.2019.03.031",
language = "English (US)",
volume = "74",
pages = "260--269",
journal = "Journal of the American College of Emergency Physicians",
issn = "0196-0644",
publisher = "Mosby Inc.",
number = "2",
}